{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:52:36Z","timestamp":1777909956311,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy of switching from cyclosporine A (CsA) 0.05% anionic emulsion (CsA AE) to CsA 0.1% cationic emulsion (CsA CE) in patients with dry eye (DE) associated with Sj\u00f6gren's syndrome (SS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Forty patients with SS-associated DE who were unresponsive to CsA AE for 6 months were enrolled. After baseline measurements, the CsA AE was switched to CsA CE. The ocular surface disease index (OSDI), Sj\u00f6gren's International Collaborative Clinical Alliance (SICCA), and Schirmer's test scores and tear film breakup time (TBUT) were evaluated at baseline and 1 and 3 months after switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two patients dropped out, and 38 were analyzed. OSDI and SICCA ocular staining scores were significantly reduced at 1 and 3 months after switching, compared with the baseline scores (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Although no significant changes were noted in the corneal staining scores (CSSs), patients with higher baseline CSS (\u22654) showed an improvement in the scores at 1 month (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.03) and 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.01) after switching. There were no significant changes in TBUT and Schirmer's test scores during the follow-up periods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with SS-associated DE, switching from CsA AE to CsA CE was effective in improving ocular symptoms and conjunctival staining. In addition, corneal staining was decreased in patients with severe keratitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0146","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T12:49:48Z","timestamp":1630068588000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sj\u00f6gren's Syndrome"],"prefix":"10.1177","volume":"37","author":[{"given":"Jonghwa","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Kyu","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Jeong","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Sok","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2788-1851","authenticated-orcid":false,"given":"Kyung Chul","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2011.06.007"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70289-6"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199811000-00002"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311801"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2014.12.001"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-015-0024-5"},{"key":"e_1_3_4_8_2","first-page":"631","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall K.","year":"2000","unstructured":"Sall K., , Stevenson O.D., , Mundorf T.K., , and Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmol. 107:631\u2013639, 2000.","journal-title":"CsA Phase 3 Study Group. Ophthalmol"},{"key":"e_1_3_4_9_2","first-page":"967","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial","volume":"107","author":"Stevenson D.","year":"2000","unstructured":"Stevenson D., , Tauber J., , and Reis B.L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 107:967\u2013974, 2000.","journal-title":"The Cyclosporin A Phase 2 Study Group. Ophthalmology"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.icl.0000170599.57728.29"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318074e460"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/604204"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31825e83f4"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12075"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S150957"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1479742"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5001002"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002244"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39859"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.09.013"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2011.25.6.421"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000779"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70148-9"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2011.25.6.369"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867033457160"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.11.1489"},{"key":"e_1_3_4_28_2","first-page":"1356","article-title":"Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes","volume":"41","author":"Brignole F.","year":"2000","unstructured":"Brignole F., , Pisella P.J., , Goldschild M., , De Saint Jean M., , Goguel A., , and Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest. Ophthalmol. Vis. Sci. 41:1356\u20131363, 2000.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_29_2","first-page":"28","article-title":"Regulation of human leukocyte antigen expression in human conjunctival epithelium","volume":"40","author":"Tsubota K.","year":"1999","unstructured":"Tsubota K., , Fukagawa K., , Fujihara T., et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. Invest. Ophthalmol. Vis. Sci. 40:28\u201334, 1999.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.04.003"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.05.025"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181a16472"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)24259-8"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31820687dd"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0270"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199801000-00007"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000952"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:26Z","timestamp":1777646666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10,1]]}},"alternative-id":["10.1089\/jop.2020.0146"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0146","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}